So close, and yet so far. As various factors finally make homeownership attainable for frequently maligned millennials, a new hurdle has appeared: Not enough houses to go around. According to recent findings by investment bank Jefferies, younger millennials between ages 25 and 29 are increasingly buying their first pads, and 30- to 34-year-olds are doing… Read More »
After multiple regulatory setbacks on Bristol Myers Squibb’s lymphoma CAR-T drug Breyanzi caused investors headaches, the company on Friday scored its second cell therapy approval. The FDA endorsed Abecma—formerly known as idecabtagene vicleucel, or ide-cel—to treat adults whose multiple myeloma has progressed after at least four previous rounds of treatment. It’s the first CAR-T med approved in multiple myeloma and the first CAR-T in… Read More »
Premier Daniel Andrews says Melburnians will soon be allowed to visit each other, but warns that homes are “the most dangerous place for the spread of this virus”. From Wednesday, two adults from one household will be able to visit another home accompanied by any dependents. Households will be restricted to one social gathering per… Read More »
It’s a brilliant feeling,” a colleague had said, misty-eyed with memories of the first taste of childhood freedom that came from learning to ride a bike. Months later, I’m sprawled on a damp grass verge in the middle of the nightly slug convention, pinned beneath a bicycle that has the same concept of freedom as… Read More »
It’s been a long road for Bristol-Myers Squibb’s Opdivo, but the immuno-oncology star finally has a place in the lucrative market for previously untreated non-small cell lung cancer. The FDA Friday approved Opdivo alongside fellow BMS checkpoint inhibitor Yervoy for first-line patients whose tumors test positive for biomarker PD-L1, giving patients a chemo-free option and… Read More »
The House Republican Study Committee has come out with a viable plan. Getty For the past ten years Republicans in Congress have been largely AWOL on health care. If memory serves, there has never been a hearing to showcase the victims of Obamacare. Nor has there been a hearing to show how sensible reforms could… Read More »